Menu Search
Equities

Basilea Pharmaceutica AG Allschwil

BSLN:SWX

Basilea Pharmaceutica AG Allschwil

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CHF)41.30
  • Today's Change0.75 / 1.85%
  • Shares traded34.24k
  • 1 Year change+15.52%
  • Beta1.0767
Data delayed at least 15 minutes, as of Nov 22 2024 16:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CHFIncome statement in CHFView more

Year on year Basilea Pharmaceutica AG Allschwil had net income fall -13.96% from 12.15m to 10.45m despite a 6.68% increase in revenues from 147.77m to 157.63m. An increase in the selling, general and administrative costs as a percentage of sales from 20.85% to 21.43% was a component in the falling net income despite rising revenues.
Gross margin76.57%
Net profit margin-0.44%
Operating margin-5.66%
Return on assets-0.31%
Return on equity-4.10%
Return on investment-0.42%
More ▼

Cash flow in CHFView more

In 2023, cash reserves at Basilea Pharmaceutica AG Allschwil fell by 44.25m. However, the company earned 14.25m from its operations for a Cash Flow Margin of 9.04%. In addition the company used 1.03m on investing activities and also paid 57.31m in financing cash flows.
Cash flow per share0.0889
Price/Cash flow per share465.19
Book value per share1.38
Tangible book value per share1.35
More ▼

Balance sheet in CHFView more

Basilea Pharmaceutica AG Allschwil has a Debt to Total Capital ratio of 85.08%, a lower figure than the previous year's 755.08%.
Current ratio4.10
Quick ratio3.27
Total debt/total equity5.70
Total debt/total capital0.8508
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.